Chargement en cours...
ELISA reagent coverage evaluation by affinity purification tandem mass spectrometry
Host cell proteins (HCPs) must be adequately removed from recombinant therapeutics by downstream processing to ensure patient safety, product quality, and regulatory compliance. HCP process clearance is typically monitored by enzyme-linked immunosorbent assay (ELISA) using a polyclonal reagent. Rece...
Enregistré dans:
| Publié dans: | MAbs |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Taylor & Francis
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5627587/ https://ncbi.nlm.nih.gov/pubmed/28708446 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2017.1349586 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|